$12.40
3.13% day before yesterday
Nasdaq, Sep 05, 10:14 pm CET
ISIN
US21900C3088
Symbol
CRMD

CorMedix Inc Stock price

$12.40
+0.35 2.86% 1M
+2.29 22.65% 6M
+4.30 53.09% YTD
+6.70 117.54% 1Y
+8.88 252.27% 3Y
+8.40 210.00% 5Y
-0.40 3.13% 10Y
-2.60 17.33% 20Y
Nasdaq, Closing price Fri, Sep 05 2025
-0.40 3.13%
ISIN
US21900C3088
Symbol
CRMD
Industry

Key metrics

Basic
Market capitalization
$925.7m
Enterprise Value
$734.9m
Net debt
positive
Cash
$190.7m
Shares outstanding
74.6m
Valuation (TTM | estimate)
P/E
17.5 | 8.8
P/S
7.6 | 4.2
EV/Sales
6.1 | 3.3
EV/FCF
24.2
P/B
4.2
Financial Health
Equity Ratio
71.2%
Return on Equity
-21.2%
ROCE
22.3%
ROIC
87.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$121.5m | $219.5m
EBITDA
$49.9m | $100.4m
EBIT
$49.3m | $116.9m
Net Income
$51.2m | $105.1m
Free Cash Flow
$30.4m
Growth (TTM | estimate)
Revenue
14,897.5% | 404.8%
EBITDA
185.9% | 555.4%
EBIT
184.8% | 623.0%
Net Income
196.3% | 685.9%
Free Cash Flow
159.4%
Margin (TTM | estimate)
Gross
95.6%
EBITDA
41.0% | 45.8%
EBIT
40.6%
Net
42.1% | 47.9%
Free Cash Flow
25.0%
More
EPS
$0.7
FCF per Share
$0.4
Short interest
19.2%
Employees
65
Rev per Employee
$670.0k
Show more

Is CorMedix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

CorMedix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a CorMedix Inc forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a CorMedix Inc forecast:

Buy
85%
Hold
15%

Financial data from CorMedix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
121 121
14,898% 14,898%
100%
- Direct Costs 5.32 5.32
300% 300%
4%
116 116
22,438% 22,438%
96%
- Selling and Administrative Expenses 59 59
15% 15%
48%
- Research and Development Expense 8.09 8.09
26% 26%
7%
50 50
186% 186%
41%
- Depreciation and Amortization 0.54 0.54
286% 286%
0%
EBIT (Operating Income) EBIT 49 49
185% 185%
41%
Net Profit 51 51
196% 196%
42%

In millions USD.

Don't miss a Thing! We will send you all news about CorMedix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CorMedix Inc Stock News

Neutral
GlobeNewsWire
5 days ago
- Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential -
Neutral
GlobeNewsWire
10 days ago
BERKELEY HEIGHTS, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in September.
Positive
Seeking Alpha
12 days ago
CorMedix has achieved GAAP profitability after years of losses, with the market yet to fully price in this turnaround. Shares trade at a moderate 17x forward P/E, but with a projected 8x forward P/E, I see further upside potential. DefenCath's FDA approval and successful commercialization underpin CorMedix's financial strength and independence from larger biotech partners.
More CorMedix Inc News

Company Profile

CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.

Head office United States
CEO Joseph Todisco
Employees 65
Founded 2006
Website cormedix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today